• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Endo Pharmaceuticals

Endo shares soar on Street-beating Q2

August 8, 2018 By Fink Densford

Endo Pharmaceuticals

Shares in Endo Pharmaceuticals (NSDQ:ENDP ) have risen nearly 20% so far today after the medical giant beat expectations on Wall Street with its second quarter results. The Dublin, Ireland-based company posted losses of $60.9 million, or 27¢ per share, on sales of $714.7 million for the three months ended June 30, seeing losses shrink 95.6% […]

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Endo Pharmaceuticals

Endo Pharmaceuticals hit with subpoena over opioid products

January 12, 2018 By Sarah Faulkner

Endo Pharmaceuticals

Endo Pharmaceuticals (NSDQ:ENDP) was hit by a grand jury subpoena yesterday from the U.S. Attorney’s Office for the Southern District of Florida over its oxymorphone products. The subpoena requests an array of documents, including those derived from past or pending lawsuits, product safety and efficacy, overdoses, diversion, theft, abuse and misuse, withdrawal and addictiveness. The attorney’s […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Endo Pharmaceuticals

FDA wants to improve access to generic abuse-deterrent opioids: here’s how

November 22, 2017 By Sarah Faulkner

FDA

The FDA commissioner, Dr. Scott Gottlieb, has made the opioid crisis a priority in his time at the agency. Yesterday, the regulatory body issued guidance to help promote the development of generic opioids designed to prevent abuse. To date, the FDA has approved 10 of these products, called abuse-deterrent opioids. But, as Gottlieb noted in […]

Filed Under: Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Endo Pharmaceuticals, FDA

Trump’s opioid public health emergency highlights differences with FDA

October 27, 2017 By Sarah Faulkner

capitol hill

President Donald Trump yesterday declared the opioid epidemic a national public health emergency – a move that he said will help “liberate our communities from this scourge of drug addiction.” The president, surrounded by lawmakers and advocates, said that the government’s plan to fight the opioid epidemic would include “really tough, really big, really great […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy, Wall Street Beat Tagged With: Endo Pharmaceuticals

Study: Abuse-deterrent opioids are costly and unproven

August 10, 2017 By Sarah Faulkner

Prescription drugs

In an attempt to curb the harrowing opioid crisis in America, drugmakers have developed what they tout as “abuse-deterrent” pain-killers – opioid formulations that are designed to prevent users from injecting the drugs. But a report published this week by the Institute of Clinical and Economic Review found that there isn’t enough evidence to claim […]

Filed Under: Featured, Pain Management, Pharmaceuticals Tagged With: Endo Pharmaceuticals

Endo swings to Q2 loss on $775m pelvic mesh set-aside

August 8, 2017 By Sarah Faulkner

Endo Pharmaceuticals

Endo International (NSDQ:ENDP) posted a net loss in the second quarter of this year, citing charges like the $775 million it has set aside to resolve 22,000 remaining lawsuits relating to the company’s vaginal-mesh implants. The generic drugmaker faced other setbacks this quarter, including the FDA asking that Endo pull its painkiller, Opana ER, from the […]

Filed Under: Featured, Implants, Legal News, MassDevice Earnings Roundup, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Endo Pharmaceuticals

Endo shutters manufacturing facilities in Huntsville

July 21, 2017 By Sarah Faulkner

Endo Pharmaceuticals

Endo (NSDQ:ENDP) said today that it plans to close its manufacturing and distribution plants in Huntsville, Alabama, slashing 875 jobs from its workforce. The closing, which is slated to happen over the next 12 to 18 months, is due to declining volumes of commoditized products, according to Endo. “Endo’s key priorities include building our product portfolio and […]

Filed Under: Featured, Pharmaceuticals, Wall Street Beat Tagged With: Endo Pharmaceuticals

Endo pulls painkiller from the market following FDA request

July 6, 2017 By Sarah Faulkner

Endo Pharmaceuticals

Endo Pharmaceuticals (NSDQ:ENDP) said today that it will voluntarily pull its Opana ER painkiller from the market. The move comes just weeks after the FDA asked the company to pull the plug on its opioid, arguing that the benefits of the abuse-deterrent drug no longer outweigh the risks. To write off the remaining net book value […]

Filed Under: Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Endo Pharmaceuticals

FDA asks Endo to pull Opana from the market over concerns of abuse

June 9, 2017 By Sarah Faulkner

Endo Pharmaceuticals

The FDA asked Endo Pharmaceuticals (NSDQ:ENDP) to pull its opioid pain med, Opana ER, from the market, saying that the benefits of the abuse-deterrent drug no longer outweigh the risks. The move marks the 1st time the federal regulatory watchdog has urged a company to remove an opioid painkiller due to concerns of abuse. “We are facing […]

Filed Under: Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Endo Pharmaceuticals

Critics allege misleading campaigns, poorly-cited data fueled opioid addiction crisis

June 2, 2017 By Sarah Faulkner

Pills

The state of Ohio filed a lawsuit against opioid-makers this week, alleging that the companies produced misleading marketing schemes to convince doctors and patients that opioids were not addictive. Ohio isn’t alone – Mississippi and West Virginia have filed similar cases against major players in the pharmaceutical industry. Purdue Pharma, Johnson & Johnson (NYSE:JNJ), Endo […]

Filed Under: Featured, Legal News, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Endo Pharmaceuticals, johnsonandjohnson, purduepharma, Teva Pharmaceuticals

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS